Protalix BioTherapeutics Inc (AMEX:PLX)
$ 1.1 -0.15 (-12%) Market Cap: 80.65 Mil Enterprise Value: 62.37 Mil PE Ratio: 55.00 PB Ratio: 2.39 GF Score: 60/100

Protalix BioTherapeutics, Inc. - Special Call Transcript

Dec 02, 2019 / 01:00PM GMT
Release Date Price: $3.24 (+4.18%)
Unidentified Participant

Good morning, everybody. Thanks for roughing the weather to join the Protalix BioTherapeutics' discussion on Fabry disease.

Today, our host will be Dr. David Warnock from University of Alabama at Birmingham. And he is joined by Protalix's CFO, Eyal Rubin; and CEO, Dror Bashan.

David G Warnock
University of Alabama at Birmingham - Director of the Division of Nephrology

Good morning. Good morning. It's a pleasure to be here. Always fun to come to New York this time of year. So as mentioned, I'm David Warnock. I am a nephrologist, a kidney doctor. And my academic career was at the University of Alabama in Birmingham for the last 25-some years. I served as the Division Director, Head of the Kidney Program. And in 2008, I recruited my replacement. And so I rode off into the horizon. And for the last 10 years, I've been basically -- I've been on Emeritus status, which means, essentially, I get to do what I want to do. And the focus, really, of my efforts over the last 10 years have largely been on Fabry disease. Alabama is an interesting

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot